Social functioning in patients with depressive and anxiety disorders

Saris, Ilja M.J.; Aghajani, Moji; Werff, Steven J.A. van der; Wee, Nic J.A. van der; Penninx, Brenda W. J. H.

doi:10.1111/acps.12774

Cited by 127 publications

(103 citation statements)

References 51 publications

(67 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Together, this puts weight to the notion of PMHC being a viable alternative for helping adults struggling with mild to moderate anxiety and depressionwith regards to symptom levels as well as daily-life functioning and work participation. In light of literature showing that functional impairment may continue also after symptom relief [5,11,12], it is highly positive to observe that the strength of the pre-post improvement in functional status (− 0.9) is close to the observed improvement in symptoms of depression (ES-1.1) and anxiety (ES-1.0) in PMHC. Also, knowing that longer absences greatly reduces prospects for return to work [59], observing the transition from receiving benefits to full return to work is encouraging.…”

Section: Discussionmentioning

confidence: 73%

“…The functional impairment is greater for these than many other common conditions, such as back pain, diabetes and arthritis [7,8]. Further, function may also be impaired among workers with subthreshold symptom levels [9,10] and after remission [5,11,12]. From an individual point of view, it is therefore not surprising that return to usual level of functioning is considered by depressed individuals themselves to be among the key facets defining remission from depression [13].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prompt Mental Health Care (PMHC): work participation and functional status at 12 months post-treatment

Knapstad

Sæther

Hensing

et al. 2020

BMC Health Serv Res

View full text Add to dashboard Cite

Background: Anxiety and depression are associated with substantial functional impairment. Prompt Mental Health Care (PMHC), the Norwegian adaptation of IAPT is currently piloted across Norway, as a means to improve access to evidence-based care for adults with anxiety disorders (including subthreshold cases) and minor to moderate depression. The aims of the current paper were to examine the change in work status and functional status from pre-to post-treatment and 12 months post-treatment among clients at the first 12 PMHC pilot sites, and whether degree of change differed across sociodemographic characteristics. Methods: A prospective cohort design was used, including working age clients receiving treatment between October 2014 and December 2016 (n = 1446, participation rate = 61%). Work status and functional status were selfreported, the latter by the Work and Social Adjustment Scale (WSAS). Changes in work status and WSAS score were examined through multilevel models based on maximum likelihood estimation. Likelihood ratio tests were performed to determine whether the interaction between time and the respective background variables were statistically significant. Results: A substantial increase in regular work participation was observed from pre-to post-treatment, which further had increased at 12 months post-treatment. The increase was driven by a corresponding reduction in proportion of clients working and receiving benefits (OR 0.38 [0.29-0.50] baseline to final treatment, OR = 0.19 [0.12-0.32] final treatment to 12-months post-treatment), while no statistically significant change was observed in proportion out of work. Large improvement (ES = − 0.89) in WSAS score was observed from pre-to post treatment. WSAS score at 12 months post-treatment remained at the post-treatment level. Conclusions: Previous research has shown substantial symptom improvement among clients receiving treatment in PMHC. The current findings indicate that PMHC might also be able to aid adults struggling with mild to moderate anxiety and depression in returning to usual level of functioning. The degree to which the observed improvements are attributable to the treatment need nonetheless to be confirmed in a trial including a control group and with more complete follow-up data from registries.

show abstract

Section: Discussionmentioning

confidence: 73%

Section: Introductionmentioning

confidence: 99%

Prompt Mental Health Care (PMHC): work participation and functional status at 12 months post-treatment

Knapstad

Sæther

Hensing

et al. 2020

BMC Health Serv Res

View full text Add to dashboard Cite

show abstract

“…In our study, mental disorder comorbidity shows an important association with perception of need for care. This is likely due to a higher severity of symptoms among persons with comorbid anxiety (Saris, Aghajani, van der Werff, van der Wee, & Penninx, 2017). There is also the possibility that some symptoms are not recognized as a mental disorder, but rather are attributed to somatic illnesses.…”

Section: Discussionmentioning

confidence: 99%

Treatment gap for anxiety disorders is global: Results of the World Mental Health Surveys in 21 countries

et al. 2018

View full text Add to dashboard Cite

Background Anxiety disorders are a major cause of burden of disease. Treatment gaps have been described, but a worldwide evaluation is lacking. We estimated, among individuals with a 12-month DSM-IV anxiety disorder in 21 countries, the proportion who: i) perceived a need for treatment; ii) received any treatment; and (iii) received possibly adequate treatment. Methods Data from 24 community surveys in 21 countries of the WMH surveys. DSM-IV mental disorders were assessed (WHO Composite International Diagnostic Interview, CIDI 3.0). DSM-IV included PTSD among anxiety disorders, while it is not considered so in the DSM-5. We asked if, in the previous 12 months, respondents felt they needed professional treatment and if they obtained professional treatment (specialized/general medical, complementary alternative medical, or non-medical professional) for “problems with emotions, nerves, mental health, or use of alcohol or drugs”. Possibly adequate treatment was defined as receiving pharmacotherapy (1+ months of medication and 4+ visits to a medical doctor) or psychotherapy, CAM or non-medical care (8+ visits). Results Of 51,547 respondents (response=71.3%), 9.8% had a 12-month DSM-IV anxiety disorder, 27.6% of whom received any treatment, and only 9.8% received possibly adequate treatment. 41.3% of those with 12-month anxiety perceived a need for care. Lower treatment levels were found for lower income countries. Conclusions Low levels of service use and a high proportion of those receiving services not meeting adequacy standards for anxiety disorders exist worldwide. Results suggest the need for improving recognition of anxiety disorders and the quality of treatment.

show abstract

“…One reason for social isolation has been suggested to be associated with the behaviors of depressed individuals. Major depressive and anxiety disorders are associated with reductions in adaptive social functioning both during the disease and after remission [24]. Thus, depression and anxiety can themselves increase the likelihood of social isolation that can, in turn, fuel the cycle of isolation and depression.…”

Section: Social Isolation and Social Supportmentioning

confidence: 99%

Facilitation of Social Support through Negative Allosteric Modulation of α5-Associated GABAA Receptors: A Novel Mechanism for the Treatment of Depression, Agitation, and Aggression in the Elderly

Witkin¹,

Golani²,

Cerne³

et al. 2019

obm geriatr

View full text Add to dashboard Cite

Major depressive disorder is a highly-prevalent and debilitating disorder in the aged population. Accumulating clinical evidence suggests a key role for social support in helping to mitigate depression. Preclinical data are reviewed that indicate that selective negative allosteric modulation of 5-containing GABA A receptors, as with RY-080, might rapidly impact depression in patients. Further, preclinical data in transgenic mice modeling neurodegenerative diseases has suggested that this mechanism might also function to reduce agitation and aggression. These data are discussed in terms of the concept of

show abstract

Social functioning in patients with depressive and anxiety disorders

Cited by 127 publications

References 51 publications

Prompt Mental Health Care (PMHC): work participation and functional status at 12 months post-treatment

Prompt Mental Health Care (PMHC): work participation and functional status at 12 months post-treatment

Treatment gap for anxiety disorders is global: Results of the World Mental Health Surveys in 21 countries

Facilitation of Social Support through Negative Allosteric Modulation of α5-Associated GABAA Receptors: A Novel Mechanism for the Treatment of Depression, Agitation, and Aggression in the Elderly

Contact Info

Product

Resources

About